Nucleoside monophosphate prodrugs that are eventually bioconverted to the active nucleoside triphosphate (NTP) offer the potential to deliver increased intracellular NTP levels and/or organ-specific NTP enhancement. There are several classes of monophosphate prodrugs that have been applied to HCV drug discovery, and some of these approaches are currently being evaluated in humans. This review discusses recent advances in monophosphate prodrug approaches to improve oral absorption, stability and pharmacokinetic profile, including their advantages and potential pitfalls.
References
1.
ChooQ.L., KuoG., WeinerA., OverbyL.R., BradleyD.W., HoughtonM.Isolation of a cDNA clone derivied from a blood-borne non-A, non-B viral hepatitis genome.Science1989; 244: 359–362.
DarbyS.C., EwartD.W., GiangrandeP.L.F.Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C.Lancet1997; 350: 1425–1431.
4.
PoynardT., RatziuV., BenhamouY., OpolonP., CacoubP., BedossaP.Natural history of HCV infection.Baillieres Best Pract Res Clin Gastroenterol2000; 14: 211–228.
5.
HoofnagleJ.H., HepatitisC.The clinical spectrum of disease.Hepatology1997; 26 Suppl 1: 15S–20S.
6.
McGuiganC., PerroneP., MadelaK., NeytsJ.The phosphoramidate ProTide approach greatly enhances the activity of β-2’-C-methylguanosine against hepatitis C virus.Bioorg Med Chem Lett2009; 19: 4316–4320.
7.
GhosnJ., LarsenC., PirothL.Evidence for ongoing epidemic sexual transmission of HCV (2006 to 2007) among HIV-1-infected men who have sex with men: France.16th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, QC, Canada. Abstract 800.
8.
FishmanS., ChildsK., DieterichD.Age and risky behaviors of HIV-infected men with acute HCV infection in New York City are similar, but not identical, to those in a European outbreak.16th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, QC, Canada. Abstract 801.
9.
MannsM.P., FosterG.R., RockstrohJ.K., ZeuzemS., ZoulimF., HoughtonM.The way forward in HCV treatment – finding the right path.Nat Rev Drug Discov2007; 6: 991–1000.
MannsM.P., McHutchisonJ.G., GordonS.C.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.Lancet2001; 358: 958–965.
12.
McCownM.F., RajyaguruS., PogamSl. The hepatitis C virus replicon presents a higher barier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.Antimicrob Agents Chemother2008; 52: 1604–1612.
13.
McHutchisonJ.G., MannsM., PatelK.Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.Gastroenterology2002; 123: 1061–1069.
14.
FriedM.W.Side effects of therapy of hepatitis C and their management.Hepatology2002; 36 Suppl 1: S237–S244.
15.
PawlotskyJ.M.Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C.Antiviral Res2003; 59: 1–11.
16.
GordonC.P., KellerP.A.Control of hepatitis C: a medicinal chemistry perspective.J Med Chem2005; 48: 1–20.
17.
KeicherJ.D., RobertsC.D., DyatkinaN.B., inventors; Genelabs Technologies, Inc. assignee. Nucleoside compounds for treating viral infections. United States patent US 0107312. 2005 May 19.
18.
WongT., LeeS.S.Hepatitis C: a review for primary care physicians.Can Med Assoc J2006; 174: 649–659.
19.
KochU., NarjesF.Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.Curr Top Med Chem2007; 7: 1302–1329.
20.
PrakashT.P., PrhavcM., EldrupA.B.Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5’-monophosphates as inhibitors of hepatitis C virus RNA replication.J Med Chem2005; 48: 1199–1210.
21.
ArendsJ.E., MudrikovaT., WensingA.M.J.High percentage of non-response with peginterferon-alfa-2a monotherapy for the treatment of acute hepatitis C in HIV infected patients.49th Interscience Conference on Antimicrobial Agents and Chemotherapy. 12–15 September 2009, San Francisco, CA, USA. Abstract H-222.
22.
De FrancescoR., MigliacciaG.Challenges and successes in developing new therapies for hepatitis C.Nature2005; 436: 953–960.
23.
HuangZ., MurrayM.G., SecristJ.A.III. Recent development of therapeutics for chronic HCV infection.Antiviral Res2006; 71: 351–362.
24.
MeppenM., PaciniB., BazzoR.Cyclic phosphoramidates as prodrugs of 2’-methylcytidine.Eur J Med Chem2009; 44: 3765–3770.
25.
MartinL.T., Cretton-scottE., PlacidiL.In vitro and in vivo metabolism and pharmacokinetics of bis[(t-butyl)-S-acyl-2-thioethyl]-β-l-2’,3’-dideoxy-5-fluorocytidine monophosphate.Nucleosides Nucleotides Nucleic Acids2000; 19: 481–499.
26.
TrautT.W.Physiological concentrations of purines and pyrimidines.Mol Cell Biochem1994; 140: 1–22.
27.
HeckerS.J., ErionM.D.Prodrugs of phosphates and phosphonates.J Med Chem2008; 51: 2328–2345.
28.
De ClercqE., FieldH.J.Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy.Br J Pharmacol2006; 147: 1–11.
29.
Poijärvi-VirtaP., LönnbergH.Prodrug approaches of nucleotides and oligonucleotides.Curr Med Chem2006; 13: 3441–3465.
30.
LiF., MaagH., AlfredsonT.Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting.J Pharm Sci2008; 97: 1109–1134.
31.
PlossA., KhetaniS.R., JonesC.T.Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures.Proc Natl Acad Sci U S A2010; 107: 3141–3145.
32.
SchinaziR.F., CoatsS.J., BassitL.C., LennerstrandJ., NettlesJ.H., HurwitzS.J.Approaches for the development of antiviral compounds: the case of hepatitis C virus.Handb Exp Pharmacol2009; 189: 25–51.
33.
DevineK.G., McGuiganC., O'ConnorT.J., NichollsS.R., KinchingtonD.Novel phosphate derivatives of zidovudine as anti-HIV compounds.AIDS1990; 4: 371–373.
34.
CahardD., McGuiganC., BalzariniJ.Aryloxy phosphoramidate triesters as Pro-Tides.Mini Rev Med Chem2004; 4: 371–381.
35.
PierraC., AmadorA., BenzariaS.Synthesis and pharmacokinetics of valopictabine (NM-283), an efficient prodrug of the potent anti-HCV agent 2’-C-methylcytidine.J Med Chem2006; 49: 6614–6620.
36.
MurakamiE., BaoH., RameshM.Mechanism of activation of β-d-2’-deoxy-2’-fluoro-2’-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.Antimicrob Agents Chemother2007; 51: 503–509.
37.
GardelliC., AttenniB., DonghiM.Phosphoramidate prodrugs of 2’-methylcytidine for therapy of hepatitus C virus infection.J Med Chem2009; 52: 5394–5407.
38.
PerroneP., LuoniG.M., KelleherM.R.Application of the phosphoramidate protide approach to 4’-azidouridine confers sub-micromolar potency versus hepatitis C virus on an inactive Nucleoside.J Med Chem2007; 50: 1840–1849.
39.
RondlaR., CoatsS.J., McBrayerT.R.Anti-hepatitis C virus activity of novel β-d-2’-C-methyl-4’-azido pyrimidine nucleoside phosphoramidate prodrugs.Antivir Chem Chemother2009; 20: 99–106.
40.
SofaM.J., DuJ., WangP., NagarathnamD., inventors; Pharmasset, Inc., assignee. Nucleoside phosphoramidate prodrugs. WO 121634. 2008 October 9.
41.
LawitzE., Rodriguez-TorresM., DenningJ.Potent antiviral activity observed with PSI-7851, a novel nucleotide polymerase inhibitor for HCV, following multiple ascending oral doses for 3 days in patients with chronic HCV infection.Global Antiviral Journal2009; 5 Suppl 1: 96.
42.
LamA.M., EspirituC., Micolochick SteuerH.M.In vitro selection and characterization of hepatitis C virus replicon variants resistant to PSI-7851, a phosphoramidate prodrug of β-d-2’-deoxy-2’-fluoro-2’-C-methyluridine monophosphate.Global Antiviral Journal2009; 5 Suppl 1: 137–138.
43.
LudmererS.W., GrahamD.J., BootsE.Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay.Antimicrob Agents Chemother2005; 49: 2059–2069.
PattiJ., AmesB., BryantD.Pharmacological properties and in vitro characterization of INX-189, a liver targeted phosphoramidate nucleoside analogue inhibitor of NS5b.60th Annual Meeting of the American Association for the Study of Liver Diseases. 30 October–3 November 2009, Boston, MA, USA. Poster 1611.
46.
KolykhalovA., ChamberlainS., GorovitsE.In vitro characterization of INX-189, a highly potent phosphoramidate nucleoside analogue inhibitor of HCV.Global Antiviral Journal2009; 5 Suppl 1: 95.
47.
PerroneP., DaverioF., ValenteR.First example of phosphoramidate approach applied to a 4’-substituted purine nucleoside (4’-azidoadenosine): conversion of an inactive nucleoside to a submicromolar compound versus hepatitis C virus.J Med Chem2007; 50: 5463–5470.
48.
GunicE., SuetyingC., FrankR.6-Hydrazinopurine 2’-methyl ribonucleosides and their 5’-monophsophate prodrugs as potent hepatitis C virus inhibitors.Bioorg Med Chem Lett2007; 17: 2456–2458.
49.
DonghiM., AttenniB., GardelliC.Synthesis and evaluation of novel phosphoramidate prodrugs of 2’-methylcytidine as inhibitors of hepatitis C virus NS5B polymerase.Bioorg Med Chem Lett2009; 19: 1392–1395.
50.
MeppenM., NarjesF., PaciniB., GardelliC., DuretteP.J., inventors; Merck & Co., Inc., Instituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A., assignees. Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection. WO 079206. 2008 July 3.
51.
EcksteinF., GishG.Phosphorothioates in molecular biology.Trends Biochem Sci1989; 14: 97–100.
52.
PérigaudC., GosselinG., LefebvreI.Rational design for cytosolic delivery of nucleoside monphosphates: ‘SATE’ and ‘DTE’ as enzyme-labile transient phosphate protecting groups.Bioorg Med Chem Lett1993; 3: 2521–2526.
ButlerT., ChoA., KimC., SaundersO.L., ZhangL., inventors; Gilead Sciences, Inc., assignee. 1’-Substituted carbanucleoside analogs for antiviral treatment. WO 132135. 2009 October 29.
55.
ChoA., KimC., ParrishJ., XuJ., inventors; Gilead Sciences, Inc., assignee. Carba-nucleoside analogs for antiviral treatment. WO 132123. 2009 October 29.
56.
DingY., GirardetJ., HongZ.Synthesis of 9-(2-β-C-methyl-β-d-ribofuranosyl)-6-substituted purine derivatives as inhibitors of HCV RNA replication.Bioorg Med Chem Lett2005; 15: 709–713.
57.
GunicE., GirardetJ.L., RamasamyK.Cyclic monophosphate prodrugs of base-modified 2’-C-methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication.Bioorg Med Chem Lett2007; 17: 2452–2455.
58.
SommadossiJ.P., GosselinG., PierraC., PerigaudC., PeyrottesS. inventors; Idenix Pharmaceuticals, Inc., Centre National de la Recherche Scientifique, L'Universite Montpellier Il., assignees. Compounds and pharmaceutical compositions for the treatment of viral infections. WO 082601. 2008 July 10.
59.
StandringD.N., PerigaudC., PeyrottesS.Pharmacology of IDX184, a liver-targeting nucleotide prodrug for the treatment of HCV.Global Antiviral Journal2009; 5 Suppl 1: 22.
60.
LalezariJ., AsmuthD., CasirA.Antiviral activity, safety and pharmacokinetics of IDX184, a liver – targeted nucleotide HCV polymerase inhibitor, in patients with chronic hepatitis C.60th Annual Meeting of the American Association for the Study of Liver Diseases. 30 October–2 November 2009, Boston, MA, USA. Poster LB18.
61.
MayersD.IDX184 – a novel, liver-targeted, once-a-day nucleoside prodrug for the treatment of chronic HCV infection.HEP DART – Frontiers in Drug Development for Viral Hepatitis. Satellite Mini-Symposium: Toward Curative Therapies for Hepatitis C. 6–10 December 2009, Kohala Coast, HI, USA.
62.
ErionM.D., BulloughD.A., LinC-C, HongZ.HepDirect PDs for targeting nucleotide-based antiviral drugs to the liver.Curr Opin Investig Drugs2006; 7: 109–117.
63.
BookserB.C., RaffaeleN.B.High-throughput synthesis of HepDirect prodrugs of nucleoside monophosphates.J Comb Chem2008; 10: 567–572.
64.
ErionM.D., ReddyK.R., BoyerS.H.Design, synthesis, and characterization of a series of cytochrome P450 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based prodrugs to the liver.J Am Chem Soc2004; 126: 5154–5163.
65.
HeckerS.J., ReddyK.R., van PoeljeP.D.Liver-targeted prodrugs of 2’-methyladenosine for therapy of hepatitus C virus infection.J Med Chem2007; 50: 3891–3896.
66.
HeckerS.J., ReddyK.R., inventors; Metabasis Therapeutics, Inc. assignee. Nucleoside prodrugs and uses thereof. WO 073506. 2009 June 11.
67.
BookserB.C., HeckerS.J., ReddyR.K., SmithD.B., SunZ., inventors; Metabasis Therapeutics Inc., assignee. Antiviral nucleoside compounds. WO 069095. 2009 June 4.
68.
HeckerS.J., ReddyK.R., SunZ., BookserB.C., SmithD.B.inventors; Roche Palo Alto LLC, assignee. Nucleoside prodrugs and uses thereof. United States patent US 0209481. 2009 August 20.
69.
WylesD.L., KaiharaK.A., KorbaB.E., SchooleyR.T., BeadleJ.R., HostetlerK. Y.. The octadecylonyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons.Antimicrob Agents Chemother2009; 53: 2660–2662.
70.
MorreyJ.D., KorbaB.E., BeadleJ.R., WylesD.L., HostetlerK. Y.. Alkoxyalkyl esters of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo.Antimicrob Agents Chemother2009; 53: 2865–2870.
71.
StandringD.IDX184, a liver-targeted nucleotide prodrug for the treatment of HCV.HEP DART – Frontiers in Drug Development for Viral Hepatitis. Satellite Mini-Symposium: Toward Curative Therapies for Hepatitis C. 6–10 December 2009, Kohala Coast, HI, USA.
MannsM.P., FosterG.R., RockstrohJ.K., ZeuzemS., ZoulimF., HoughtonM.The way forward in HCV treatment-finding the right path.Nat Rev Drug Discov2007; 6: 991–1000.
75.
SchinaziR.F., BassitL., GavegnanoC.HCV drug discovery aimed at viral eradication.J Viral Hepat2010; 17: 77–90.
76.
McGuiganC., PerroneP., inventors; University College Cardiff Consultants Limited, KU Leuven Research and Development, assignees. Chemical Compounds. WO 062206. 2008 May 29.
